{"id":6045,"date":"2019-09-24T15:17:49","date_gmt":"2019-09-24T09:47:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6045"},"modified":"2021-07-24T12:57:33","modified_gmt":"2021-07-24T07:27:33","slug":"recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","title":{"rendered":"Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial"},"content":{"rendered":"\n

Flagship Pioneering has launched Omega Therapeutics with an aim to take\nforward the genomic medicine. <\/strong><\/h4>\n\n\n\n

The launch of Omega therapeutics\nwas planned to focus on epigenetic drugs to target diseases. Study of changes\nin gene expressions without any changes in the DNA sequence is known as Epigenetics.\n This often includes the addition of\nextra molecules that control the expression of genes. <\/p>\n\n\n\n

Omega therapeutics has launched an exclusive platform that adjusts Insulated Genomic Domains (IGDs) of the human genome. Many diseases, including cancer, heart disease<\/a>, diabetes<\/a>, and mental illnesses are influenced by epigenetic mechanisms, and epigenetic therapy offers a potential way to influence those pathways directly.<\/p>\n\n\n\n

At present, there exist only a few epigenetic drugs including Zolinza (vorinostat) developed by Merck for the treatment of Lymphoma, Otsuka Pharmaceutical\u2019s Dacogen (decitabine) for myelodysplastic syndrome, Novartis\u2019s Farydak (panobinostat) for multiple myeloma and Vidaza (azaacitidine) of Pharmion for myelodysplastic syndrome. <\/p>\n\n\n\n

These drugs target enzymes that are\ninvolved in the regulation of gene expression. <\/p>\n\n\n\n

The European Medicines Agency has given its recommendation for Bayer\u2019s and\nLilly\u2019s Vitrakvi for the treatment of NTRK fusion-positive cancers. <\/strong><\/h4>\n\n\n\n

Vitrakvi (larotrectinib) has received FDA\u2019s nod last year in the month of November. It is a drug which targets the tumour based on genetic markers for cancers <\/a>that are a result of a genomic abnormality called NTRK fusion. <\/p>\n\n\n\n

Originally co-developed by Bayer\nand Loxo Oncology, the latter which was afterwards acquired by Lilly for an\namount of USD 8Billion. <\/p>\n\n\n\n

Vitrakvi is a second drug after Merck\u2019s Keytruda that is tumour-agnostic. Roche\u2019s Rozlytrek (entrectinib) became the third drug to get approval from the FDA to target NTRK fusion and ROS1 in lung cancer. <\/p>\n\n\n\n

Bluebird Bio, a biotechnology firm has reported positive results from\nthe Phase II\/III clinical trials of Lenti-D gene therapy to target cerebral\nadrenoleukodystrophy (CALD).<\/strong><\/h4>\n\n\n\n

CALD, a rare genetic disorder can\nresult in severe loss of neurologic function and death.<\/p>\n\n\n\n

The Starbeam trial, intended to gauge\nthe safety and efficacy of Lenti-D in boys aged 17 and under. Its primary\nefficacy endpoint is the proportion of patients alive and free of major\nfunctional disabilities (MFDs) at 24 months.<\/p>\n\n\n\n

The results were primarily based\non the proportion of patients alive and free of major functional disabilities\n(MFDs) at 24 months.  <\/p>\n\n\n\n

The data revealed that 88% of\npatients who underwent therapy and stayed under supervision for 24 months were\nfree of major functional disabilities (MFDs) at two years and remained the same\nfor up to five years.<\/p>\n\n\n\n

MFDs are a group of symptoms comprising loss of communication ability, total incontinence, and complete loss of voluntary movement, the need for tube feeding, cortical blindness and wheelchair dependence. The company is also running observational study of allogeneic hematopoietic stem cell transplant (allo-HSCT) in CALD patients which gave favourable results. <\/p>\n","protected":false},"excerpt":{"rendered":"

Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics.  This often includes the addition of extra molecules […]<\/p>\n","protected":false},"author":1,"featured_media":6046,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[124,1271,17784,639,5789],"industry":[17225],"therapeutic_areas":[17238,17228,17234],"class_list":["post-6045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bluebird-bio","tag-delveinsight-pharma-news","tag-omega-therapeutics","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nFlagship Pioneering launches Omega Therapeutics<\/title>\n<meta name=\"description\" content=\"Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine to focus on epigenetic drugs to cure diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Flagship Pioneering launches Omega Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine to focus on epigenetic drugs to cure diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-24T09:47:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Flagship Pioneering launches Omega Therapeutics","description":"Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine to focus on epigenetic drugs to cure diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","og_locale":"en_US","og_type":"article","og_title":"Flagship Pioneering launches Omega Therapeutics","og_description":"Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine to focus on epigenetic drugs to cure diseases.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-09-24T09:47:49+00:00","article_modified_time":"2021-07-24T07:27:33+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega","name":"Flagship Pioneering launches Omega Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019.png","datePublished":"2019-09-24T09:47:49+00:00","dateModified":"2021-07-24T07:27:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine to focus on epigenetic drugs to cure diseases.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-blue-bird-bio-bayer-lilly-omega#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019.png","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/09020805\/News-24.09.2019-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bluebird bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Omega Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bluebird bio<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">Omega Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 24, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 24, 2019 3:17 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6045"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6045\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6046"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6045"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6045"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}